This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ARQ 197, ARQ-197, ARQ197
Description: ARQ 197 is designed to block the activity of c-Met, a receptor tyrosine kinase that is thought to play multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. Pre-clinical findings have demonstrated that ARQ 197 inhibits c-Met in a wide range of human tumor cell lines and possesses anti-tumor activity against several types of xenografted human tumors in mice.
ArQule and Kyowa Hakko Kogyo
ArQule announced in April 2007 that it has entered into an exclusive license agreement with Kyowa Hakko Kogyo Co., Ltd. (Kyowa) to develop and commercialize ARQ 197 in Japan and parts of Asia.
The agreement includes $123 million in upfront and potential development milestone payments from Kyowa to ArQule, including a $30 million cash upfront licensing payment. In addition, the agreement includes undisclosed sales milestone payments. Upon commercialization, ArQule will receive double-digit royalties from Kyowa on net sales of ARQ 197. Kyowa will be responsible for clinical development costs and commercialization of the compound in certain Asian countries, consisting of Japan, China (including Hong Kong), South Korea and Taiwan.
ArQule and Daiichi Sankyo
In November 2008, ArQule and Daiichi Sankyo entered into a binding letter of intent for an exclusive license, co-development and co-commercialization agreement under which they...See full deal structure in Biomedtracker
Partners: Kyowa Hakko Kirin Co., Ltd. Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: